<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33787016</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1853-0605</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)</Title><ISOAbbreviation>Rev Fac Cien Med Univ Nac Cordoba</ISOAbbreviation></Journal><ArticleTitle>[Long covid: cross sectional study].</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>36</EndPage><MedlinePgn>33-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31053/1853.0605.v78.n1.32048</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Coronavirus disease 2019 (COVID-19) is a public health problem worldwide. After 3 weeks of the onset of the disease, between 10-87% of patients persist with symptoms. The objective of the study was to evaluate the persistence of symptoms in patients with COVID-19, the associated factors, and to explore the patients' perception of the disease.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We conducted a cross-sectional study that included 85 patients with a confirmed diagnosis of COVID-19, who attended on an outpatient basis after the acute phase (&gt; 3 weeks) of the disease.</AbstractText><AbstractText Label="RESULTS">The median time from diagnosis to outpatient consultation was 53 days (interquartile range 31-65). Most (86%) had mild disease, 45% were women and the mean age was 43 years (standard deviation of 13). After the acute phase of the disease 52% (95% CI 41-63%) of the patients persisted with symptoms. The most frequently persistent symptoms were fatigue (49%) and cough (33%). Nineteen percent had insomnia and sixteen percent had anxiety. Female sex, obesity, age between 35-55 years, and initial hospitalization were associated with the persistence of symptoms. Twenty percent of the patients stopped following the prevention recommendations because they believed they were immunized.</AbstractText><AbstractText Label="CONCLUSION">More than half of the patients persisted with symptoms 3 weeks after the COVID-19 diagnosis, so medical follow-up is important. Female sex, obesity, age 35-55 years, and initial hospitalization were associated factors. The symptoms usually resolved over time.</AbstractText><CopyrightInformation>Universidad Nacional de C&#xf3;rdoba</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Manuel Antonio</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Central de Emergencias de Adultos. Hospital Italiano de San Justo Agust&#xed;n Rocca, Buenos Aires, Argentina.. manuel.prieto@hospitalitaliano.org.ar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Docente de la Universidad de Buenos Aires. omarprieto@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Horacio Matias</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Neumonologia, Hospital Italiano de Buenos Aires, Argentina. . matias.castro@hospitalitaliano.org.ar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Covid prolongado: estudio de corte transversal.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Rev Fac Cien Med Univ Nac Cordoba</MedlineTA><NlmUniqueID>8303003</NlmUniqueID><ISSNLinking>0014-6722</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N">La enfermedad por Coronavirus 2019 (COVID-19) es un problema de salud p&#xfa;blica a nivel mundial. Posterior a las 3 semanas de iniciado el cuadro entre un 10-87% de los pacientes persisten con s&#xed;ntomas. El objetivo del estudio fue evaluar la persistencia de los s&#xed;ntomas en pacientes que presentaron la COVID-19, los factores asociados y explorar la percepci&#xf3;n de los pacientes sobre la enfermedad.</AbstractText><AbstractText Label="MATERIALES Y M&#xc9;TODOS">Se realiz&#xf3; un estudio de corte transversal que incluy&#xf3; 85 pacientes con diagn&#xf3;stico confirmado de COVID-19, que consultaron en forma ambulatoria posterior a la fase aguda (&gt; 3 semanas) de la enfermedad.</AbstractText><AbstractText Label="RESULTADOS">La mediana de tiempo desde el diagn&#xf3;stico a la consulta ambulatoria fue de 53 d&#xed;as (rango inter cuartil 31-65). La mayor&#xed;a (86%) present&#xf3; un cuadro leve y no requiri&#xf3; internaci&#xf3;n. El 45% eran mujeres y la media de edad fue de 43 a&#xf1;os (desv&#xed;o est&#xe1;ndar de 13). El 52% (IC95% 41-63%) de los pacientes persist&#xed;an con s&#xed;ntomas m&#xe1;s all&#xe1; de la fase aguda de la enfermedad. El s&#xed;ntoma que persisti&#xf3; con m&#xe1;s frecuencia fue la fatiga (49%) seguida de la tos (33%). El 19% present&#xf3; insomnio y el 16% ten&#xed;a ansiedad. El sexo femenino, la obesidad, la edad entre 35-55 a&#xf1;os y la hospitalizaci&#xf3;n inicial, se asociaron a la persistencia de los s&#xed;ntomas. Un 20% de los pacientes dej&#xf3; de seguir las recomendaciones de prevenci&#xf3;n porque cre&#xed;a estar inmunizado.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N">M&#xe1;s de la mitad de los pacientes persist&#xed;an con s&#xed;ntomas posterior a las 3 semanas del diagn&#xf3;stico de COVID-19. El sexo femenino, la obesidad, la edad 35-55 a&#xf1;os y la hospitalizaci&#xf3;n inicial fueron factores asociados. Los s&#xed;ntomas se fueron resolviendo con el transcurso del tiempo.</AbstractText><CopyrightInformation>Universidad Nacional de C&#xf3;rdoba</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">symptoms, fatigue</Keyword><Keyword MajorTopicYN="N">follow up studies</Keyword></KeywordList><CoiStatement>
<b>Conflicto de inter&#xe9;s:</b>
No se reporta conflicto de intereses.
</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33787016</ArticleId><ArticleId IdType="pmc">PMC8713373</ArticleId><ArticleId IdType="doi">10.31053/1853.0605.v78.n1.32048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins Coronavirus Resource Center  Home.  [consultado el 31 de octubre de 2020].  Disponible en:
 https://coronavirus.jhu.edu/
</Citation></Reference><Reference><Citation>Grant MC, Geoghegan L, Arbyn M, et al. The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. PLoS One. 2020;23:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310678</ArticleId><ArticleId IdType="pubmed">32574165</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID Symptom Study. How long does COVID-19 last? Kings College; London: 2020.  [octubre de 2020].  Disponible en:
 https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI
.</Citation></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: What do we know about &#x201c;long covid&#x201d;. BMJ. 2020:370</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen, et al. Follow-up of adults with non-critical COVID-19 two months after symptoms&#x2019; onset. Clin Microbiol Infect. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. E Clinical Medicine. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Lu Y, Huang YM, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7521361</ArticleId><ArticleId IdType="pubmed">33002478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousseff M, Penot P, Gallay L, et al. Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound. J Infect. 2020;81:816&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326402</ArticleId><ArticleId IdType="pubmed">32619697</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499500</ArticleId><ArticleId IdType="pubmed">32840608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169:2142&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>